Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaOlga Kondrashova, L. Green, Robert Holian et al.|Nature Communications|2018Cited by 299
Prognostic gene expression signature for high-grade serous ovarian cancerJoshua Millstein, Scott D. Brown, Timothy Budden et al.|Annals of Oncology|2020Cited by 173
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analysesEun Young Kang, P. Mackenzie, Dane Cheasley et al.|Modern Pathology|2020Cited by 43
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistanceKsenija Nešić, Harold C. Sullivan, Yoke-Eng Chiew et al.|Molecular Cancer|2024Cited by 28